Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced ZORYVE's coverage expansion for plaque psoriasis, with eight additional national and regional health plans now covering the treatment without prior authorization, effective April 1, 2023. This brings commercial coverage to over 110 million lives in the U.S. ZORYVE, a steroid-free topical cream, is designed for all affected body areas and offers rapid results for difficult regions. The company's responsible pricing strategy is gaining traction among payers, and they aim to enhance dermatology adoption. ZORYVE is available by prescription only, with patient assistance programs in place for eligible uninsured or underinsured patients.
Arcutis Biotherapeutics (ARQT) announced significant data from its pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 studies for roflumilast cream 0.15% in treating atopic dermatitis (AD). Results indicated rapid and notable improvements in itch relief within 24 hours of the first application. The studies demonstrated a 75% reduction in Eczema Area and Severity Index (EASI-75) in over 40% of subjects by Week 4, with favorable safety outcomes. Roflumilast cream also met the primary endpoint of IGA Success, showing a vIGA-AD score improvement. The company plans to submit a supplemental new drug application (sNDA) to the FDA later this year.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced six presentations at the 2023 American Academy of Dermatology (AAD) annual meeting in New Orleans, from March 17-21, 2023. Key highlights include late-breaking data on roflumilast cream 0.15% for atopic dermatitis from Phase 3 trials INTEGUMENT-1 and INTEGUMENT-2. Additional insights from national surveys on seborrheic dermatitis were shared, covering disease burden and treatment patterns. Roflumilast is a PDE4 inhibitor being developed for multiple dermatological conditions, including psoriasis and seborrheic dermatitis. Presentations will feature clinical safety and efficacy data, enhancing Arcutis' commitment to innovation in immuno-dermatology.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the grant of 27,550 restricted stock units to four newly hired employees under the 2022 Inducement Plan. This award, approved by the Compensation Committee, aims to attract talent as part of the company’s growth strategy. The stock units will vest over four years, with 25% vesting annually, contingent upon continuous employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and emphasizes Arcutis' commitment to addressing dermatological conditions through innovation and a robust pipeline of clinical programs for inflammatory diseases like plaque psoriasis and atopic dermatitis.
Arcutis Biotherapeutics reported net revenues of $3.0 million for ZORYVE® in Q4 2022, marking its first full quarter since launch in August 2022. The company secured expanded payer coverage and announced positive trial results for atopic dermatitis. A New Drug Application for roflumilast foam was submitted for seborrheic dermatitis, and the first patient was enrolled in a study for alopecia areata. Arcutis ended 2022 with approximately $410 million in cash. Although R&D expenses increased year-over-year primarily due to the Ducentis acquisition, the company aims for long-term growth through a broad pipeline.
Arcutis Biotherapeutics (Nasdaq: ARQT) submitted a New Drug Application (NDA) to the FDA for roflumilast foam 0.3%, targeting moderate to severe seborrheic dermatitis, affecting over 10 million people in the U.S. If approved, it would be the first topical treatment with a new mechanism in over 20 years. The pivotal Phase 3 trial showed that 80% of participants achieved 'IGA Success' at week 8, with significant improvements in itch, scaling, and erythema. Roflumilast foam demonstrated a favorable safety profile, with over 90% treatment adherence. The foam aims to simplify treatment for this chronic condition.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced a quarterly investor conference call scheduled for February 28, 2023, at 4:30 p.m. ET, where it will present its fourth quarter and full year financial results along with a business update. The company is also set to participate in the Cowen 43rd Annual Healthcare Conference on March 7, with a fireside chat and a dermatology panel discussion scheduled. Arcutis is focused on developing innovations in immuno-dermatology, with a robust pipeline addressing various inflammatory dermatological conditions.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 50,250 restricted stock units and options to purchase 8,000 shares to seven new employees, as part of the 2022 Inducement Plan. These awards were approved by the Compensation Committee and are aimed at attracting talent in the company's early commercial-stage environment, effective February 1, 2023. The stock options have a ten-year term and an exercise price of $16.84 per share. The restricted stock units vest over four years, with a 25% annual vesting schedule. Arcutis is committed to addressing urgent needs in immuno-dermatology through its innovative therapies and clinical programs.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced promising long-term data from its Phase 2 study of roflumilast cream (0.3%), an FDA-approved treatment for chronic plaque psoriasis. The study, presented at the Winter Clinical dermatology meeting, showed that 57.1% of participants achieved an Investigator Global Assessment (IGA) score of clear or almost clear, with a median duration of 40.1 weeks. Efficacy remained consistent over 52 weeks, and the cream was well-tolerated with low discontinuation rates. Key findings included sustained IGA success across different patient cohorts and no signs of tachyphylaxis, reinforcing roflumilast cream's position as a preferred treatment for psoriasis.
On January 5, 2023, Arcutis Biotherapeutics (Nasdaq: ARQT) announced the granting of 17,050 restricted stock units and options for 33,550 shares to five new employees. These awards, approved by the Compensation Committee, are part of the 2022 Inducement Plan and are intended to incentivize new hires. The restricted stock units will vest over four years, while the stock options will also vest over the same period with specific vesting schedules. The options have a ten-year term with an exercise price of $14.77, reflecting the stock's closing price on the grant date.